These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38040274)

  • 1. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
    Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
    J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
    N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
    Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M
    J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ozanimod: A Review in Ulcerative Colitis.
    Paik J
    Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
    Aoun R; Hanauer S
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C; Ungaro R; Mehandru S; Colombel JF
    Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.
    Cohen NA; Choi D; Garcia N; Choi NK; Picker E; Krugliak Cleveland N; Cohen RD; Dalal SR; Pekow J; Rubin DT
    Dig Dis Sci; 2024 Feb; 69(2):579-587. PubMed ID: 38087126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
    Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG
    Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
    Sands BE; Schreiber S; Blumenstein I; Chiorean MV; Ungaro RC; Rubin DT
    J Crohns Colitis; 2023 Dec; 17(12):2012-2025. PubMed ID: 37436357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.